drugset
drugset / Trial / NCT03058419

A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects

NCT03058419 ↗

Phase 1 Completed 16 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to determine the potential inhibitory/inducing effects of JNJ-54175446 after single and repeated dosing on the single-dose pharmacokinetics (PK) of a cocktail, containing selective probes of cytochrome P450 (CYP) enzymes (CYP3A4/A5, CYP2C9, CYP1A2, CYP2D6, CYP2B6, and CYP2C19) in healthy adult subjects.

Timeline

Start
2017-03-14
Primary completion
2017-05-15
Completion
2017-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg Oral
Subject Caffeine Small molecule 50 mg Oral
Subject Dextromethorphan Unknown 30 mg Oral
Subject JNJ-54175446 Small molecule 150 mg Oral
Subject JNJ-54175446 Small molecule 600 mg Oral
Subject Midazolam Small molecule 2 mg Oral
Subject Omeprazole Other / unclassified 20 mg Oral
Subject Warfarin Small molecule 10 mg Oral

Indications

No indication recorded.